Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.FLKS · Entity 937 | Director | July 25, 2018 | July 26, 2018 |
| Notable Labs, Ltd.VBLT · Entity 87239 | Director | January 01, 2023 | January 04, 2023 |
| UFP TECHNOLOGIES INCUFPT · Entity 4409 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date July 25, 2018 · Filed July 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-07-25 | Direct | 10,000 |
Reported balance
After 2018-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-25 · Grant · Acquired 10,000 · Balance 10,000 F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018.
Notable Labs, Ltd.
Report date January 01, 2023 · Filed January 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Marc D. Kozin Irrevocable Trust | 39,000 |
Reported balance
Holding disclosure · report date 2023-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 39,000 F1: These shares are held by the Marc D. Kozin Irrevocable Trust, of which the Reporting Person's spouse is one of the beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2036-05-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: These options were granted on 05/05/16 under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2040-11-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: These options were granted on 11/24/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on November 24, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2041-07-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: These options were granted on 07/20/21 under the 2014 Plan, with 25% of the shares underlying these options vesting on July 20, 2022 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2041-12-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F5: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2042-01-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F6: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by the Marc D. Kozin Irrevocable Trust, of which the Reporting Person's spouse is one of the beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.
F2: These options were granted on 05/05/16 under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
F3: These options were granted on 11/24/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on November 24, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
F4: These options were granted on 07/20/21 under the 2014 Plan, with 25% of the shares underlying these options vesting on July 20, 2022 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
F5: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
F6: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
UFP TECHNOLOGIES INC
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 21,112 |
Ending reported balance
After 2026-08-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-25 · Sale · Disposed 3,650 · Balance 24,462 F1: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $303.58 to $304.49, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Row 2 · 2026-08-25 · Sale · Disposed 3,350 · Balance 21,112 F2: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $304.64 to $305.41, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Filing footnotes · ownership attribution and instrument terms
F1: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $303.58 to $304.49, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $304.64 to $305.41, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHIMERIX INC
Report date April 21, 2025 · Filed April 21, 2025
Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2034-03-19 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-21 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2034-06-19 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]
F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.
F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).
Dicerna Pharmaceuticals Inc
Report date December 28, 2021 · Filed December 29, 2021
Section 16 reporting ended · disclosed 2021-12-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 1
1 source rowRow 1 · 2021-12-28 · Disposition to issuer · Disposed 6,333 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Common StockSEC Table I · non-derivative | IndirectBy Marc D. Kozin Revocable Trust | 0 |
Reported balance
After 2021-12-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-28 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.31 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.47 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
ENDOCYTE INC
Report date December 21, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2018-12-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2018-12-21 · Disposition to issuer · Disposed 3,300 · Balance 0 F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.71 · Expires 2022-07-25 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.94 · Expires 2023-06-19 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2024-05-15 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.02 · Expires 2025-05-14 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2026-05-05 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2027-05-04 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2028-05-03 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Isleworth Healthcare Acquisition Corp.
Report date September 08, 2021 · Filed September 10, 2021
Section 16 reporting ended · disclosed 2021-09-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-09-08 transaction · row 1
1 source rowRow 1 · 2021-09-08 · Other · Disposed 36,000 · Balance 0 F1: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation.
Tempest Therapeutics, Inc.
Report date December 07, 2018 · Filed December 12, 2018
Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,740 |
Reported balance
After 2018-12-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-12-07 · Grant · Acquired 831 · Balance 7,740 F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.
F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2017 Filed Jun 24, 2017 00:55 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001179110-17-009552 · edgar.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option will vest in twelve equal monthly installments at the end of each successive month following June 21, 2017. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:10 UTC | UFP TECHNOLOGIES INC UFPT · Entity 4409 | GrantStock Option (Right to Buy) · Derivative | 2,056 | $0.00 Strike: $27.05 | $0.00 |
DisclosureSEC source: 0001240679-17-000032 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,056 Underlying: Common Stock, $.01 Par Value · 2,056 shares Expires 2027-06-06 Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:10 UTC | UFP TECHNOLOGIES INC UFPT · Entity 4409 | GrantCommon Stock, $.01 Par Value | 647 | $0.00 | $0.00 |
DisclosureSEC source: 0001240679-17-000032 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,721 F1 · shares: Represents shares issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan Read SEC document |
| May 04, 2017 Filed May 5, 2017 21:07 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001179110-17-006711 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2027-05-04 F2 · derivative.exercise_date: 100% of options vest on the business day prior to the next annual stockholder meeting following the date of grant. Read SEC document |
| May 04, 2017 Filed May 5, 2017 21:07 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006711 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · shares: Represents restricted stock units that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant, and will be paid in the form of one share of common stock for each restricted stock unit. Read SEC document |
| March 31, 2017 Filed Apr 5, 2017 01:02 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantCommon Stock | 5,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005741 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,287 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document |
| December 30, 2016 Filed Jan 5, 2017 01:29 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantCommon Stock | 6,331 | $1.53 | $9,686.43 |
DisclosureSEC source: 0001179110-17-000419 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,107 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 21:12 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantCommon Stock | 1,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030318 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,776 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.